Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu] Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)
Loading...
Date
Authors
Ahmadzadehfar, Hojjat
Rahbar, Kambiz
Baum, Richard P.
Seifert, Robert
Kessel, Katharina
Bogemann, Martin
Kulkarni, Harshad R.
Zhang, Jingjing
Gerke, Carolin
Fimmers, Rolf
Journal Title
Journal ISSN
Volume Title
Publisher
Springer
Abstract
Please read abstract in the article.
Description
This article is part of the Topical Collection on Oncology - Genitourinary
Keywords
Radioligand therapy, Lu-PSMA, Chemotherapy, Castration-resistant prostate cancer (CRPC), Metastatic CRPC (mCRPC)
Sustainable Development Goals
Citation
Ahmadzadehfar, H., Rahbar, K., Baum, R.P. et al. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial) European Journal of Nuclear Medicine and Molecular Imaging, 48, 113–122 (2021). https://doi.org/10.1007/s00259-020-04797-9.